NewAmsterdam Pharma Revenue and Competitors
Estimated Revenue & Valuation
- NewAmsterdam Pharma's estimated annual revenue is currently $5M per year.
- NewAmsterdam Pharma's estimated revenue per employee is $155,000
Employee Data
- NewAmsterdam Pharma has 32 Employees.
- NewAmsterdam Pharma grew their employee count by 14% last year.
NewAmsterdam Pharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CFO | Reveal Email/Phone |
2 | CEO New Amsterdam Pharma | Reveal Email/Phone |
3 | EVP, Head CMC | Reveal Email/Phone |
4 | EVP Marketing and Medical Affairs | Reveal Email/Phone |
5 | EVP | Reveal Email/Phone |
6 | EVP, Enterprise Operations | Reveal Email/Phone |
7 | Executive Director, Clinical Operations | Reveal Email/Phone |
8 | Executive Director | Reveal Email/Phone |
9 | Chief Business Officer | Reveal Email/Phone |
10 | Chief Legal Officer, Chief Compliance Officer and General Counsel | Reveal Email/Phone |
NewAmsterdam Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is NewAmsterdam Pharma?
Founded in 2019, NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (TA-8995), a novel, selective, cholesteryl ester transfer protein (CETP) inhibitor. The Company is investigating obicetrapib as the preferred LDL-c lowering therapy for patients who cannot be treated optimally with current available lipid-lowering therapy or for patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally tolerated statin therapy. In January 2020, NewAmsterdam completed its Series A funding round of $196M (€160M) which will support the full Phase 3 development of obicetrapib.
keywords:N/A
N/A
Total Funding
32
Number of Employees
$5M
Revenue (est)
14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
NewAmsterdam Pharma News
ROSE2 study evaluates obicetrapib, a novel cholesteryl ester transfer protein (CETP) inhibitor, in combination with ezetimibe, a cholesterol...
NewAmsterdam Pharma Doses First Patient in its PREVAIL Study. PREVAIL evaluates whether obicetrapib, a novel cholesteryl ester transfer protein...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $5.2M | 32 | -18% | N/A |
#2 | $3.7M | 32 | N/A | N/A |
#3 | $3.7M | 32 | N/A | N/A |
#4 | $6.4M | 32 | N/A | N/A |
#5 | $3.7M | 32 | N/A | N/A |